Combination Drug Therapy for the Management of Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Even though the number of AD patients is rapidly growing, there is no effective treatment for this neurodegenerative disorder. At present, implementation of effective treatment approaches for AD is vital to meet clinical needs. In AD research, priorities concern the development of disease-modifying therapeutic agents to be used in the early phases of AD and the optimization of the symptomatic treatments predominantly dedicated to the more advanced AD stages. Until now, available therapeutic agents for AD treatment only provide symptomatic treatment. Since AD pathogenesis is multifactorial, use of a multimodal therapeutic intervention addressing several molecular targets of AD-related pathological processes seems to be the most practical approach to modify the course of AD progression. It has been demonstrated through numerous studies, that the clinical efficacy of combination therapy (CT) is higher than that of monotherapy. In case of AD, CT is more effective, mostly when started early, at slowing the rate of cognitive impairment. In this review, we have covered the major studies regarding CT to combat AD pathogenesis. Moreover, we have also highlighted the safety, tolerability, and efficacy of CT in the treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the combination use of appropriate cholinesterase inhibitors, such as donepezil (4) and galantamine (6), or the combination of cholinesterase inhibitors with other neurologic drugs, metal chelators, or antioxidants, may yield surprising effects in the management of cholinergic drugs in AD, including efficacy, tolerability, and safety.402,408”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [402]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Lipton, S. A., Choi, Y.-B., Pan, Z.-H., Lei, S. Z., Chen, H.-S. V., Sucher, N. J., Loscalzo, J., Singel, D. J., & Stamler, J. S. (1993) · Nature · doi:10.1038/364626a0 · Cited by 2,433
Nichols, E., Szoeke, C. E. I., Vollset, S. E., Abbasi, N., Abd-Allah, F., Abdela, J., Aichour, M. T. E., Akinyemi, R. O., Alahdab, F., Asgedom, S. W., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30403-4 · Cited by 2,412
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113
Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond
Lipton, S. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1958 · Cited by 909
Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial
Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764
Cited by
Items 101–200 of 218
Rana, R., Mishra, K., Tripathi, S., Gupta, A. K., Tiwari, A. K., Yadav, P. K., Kumar, A., Chakradhar, J. V. U. S., Singh, S., Verma, S., et al. (2024) · Bioanalysis · doi:10.1080/17576180.2024.2344395 · Cited by 8
Rani, A., Khan, J., Choudhary, L., Kumar, M., Jha, A., Pandey, G., & Nand, B. (2025) · Tetrahedron · doi:10.1016/j.tet.2025.134517 · Cited by 11
Novel Pharmaceutical Approaches in Dementia
Tanaka, M., Török, N., & Vécsei, L. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_444 · Cited by 13
Ma, L., Meng, T., Wang, Y., Xue, Y., Zheng, Y., Chen, J., Xu, D., Sun, J. L., Yang, F., Huang, J., et al. (2024) · Talanta · doi:10.1016/j.talanta.2024.126938 · Cited by 8
Alzheimer's disease: Current concept and a new hope with siRNA-liposomal system
Abla, K. K., & Zahwi, M. K. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106409 · Cited by 10
Simakov, A., Chhor, S., Ismaïli, L., & Martin, H. (2025) · Molecules · doi:10.3390/molecules30092048 · Cited by 9
“Given the complex etiopathology of AD, it has become evident that employing a combined approach targeting multiple molecular targets of AD may lead to greater therapeutic success [22].”
Preethy, H. A., Rajendran, K., Mishra, A., Karthikeyan, A., Chellappan, D. R., Ramakrishnan, V., & Krishnan, U. M. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104999 · Cited by 8
Zidan, E. F., El-Mezayen, N. S., El‐Rewini, S. H., Afify, E. A., & Ali, M. A. (2024) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-024-10159-1 · Cited by 8
Casoli, T., Giuli, C., Balietti, M., Fabbietti, P., & Conti, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145110 · Cited by 7
Capturing Knowledge about Drug-Drug Interactions to Enhance Treatment Effectiveness
Rivas, A., & Vidal, M.-E. (2021) · International Conference on Knowledge Capture · doi:10.1145/3460210.3493560 · Cited by 7
“The treatment T3 is for Alzheimer’s disease and is extracted from the paper [15].”
BackgroundChvojková, M., Kubová, H., & Valeš, K. (2021) · Brain Sciences · doi:10.3390/brainsci11030400 · Cited by 7
“Such an approach may lead to increased therapeutic effects and an improved side effect profile [42], which would be of great benefit.”
BackgroundChen, Z. S., Yan, M., Pei, W., Yan, B., Huang, C., & Chan, H. Y. E. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.07.133 · Cited by 7
Emerging Novel Therapeutic Approaches for the Treatment of Alzheimer’s Disease
Panwar, A., Khan, M. I. K., Kumar, R., Kumar, R., Kumar, S., & Kumar, A. (2024) · Advances in Alzheimer s Disease · doi:10.4236/aad.2024.133006 · Cited by 5
Kiruthiga, N., Chandrasekaran, R., Rajamanikandan, S., Joseph, J., & Aasaithambi, K. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04312-8 · Cited by 5
“Interestingly, standard drugs like donepezil, galantamine, and rivastigmine and their interaction pattern with ACE revealed a very low score when compared with betanin scores [ 38 ].”
Duggan, M. R., Ahooyi, T. M., Parikh, V., & Khalili, K. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00424-0 · Cited by 6
Salmani, M., Anoush, M., Kalantari‐Hesari, A., Maleki, A. J., Nouri, F., Hosseini, M., & Mohammadi, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-25869-6 · Cited by 6
“High doses of AchEIs as monotherapy or combination therapy for moderate to advanced dementia have shown better outcomes in AD patients, which correlated to some adverse effects, including bradycardia, an increased risk of syncope, and gastrointestinal dysfunction 14–16 .”
Chen, C., Mo, M., Åkerman, M., Ptacek, S. G., Xu, H., & Eriksdotter, M. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01918-0 · Cited by 5
“This shift is consistent with clinical practice, where the combination of ChEIs and memantine has been increasingly adopted due to its perceived synergistic benefits in slowing cognitive decline [23, 24].”
Chudhary, M. (2025) · Chemical Papers · doi:10.1007/s11696-025-04532-4 · Cited by 6
Coumarin compounds against Alzheimer's disease: An in-silico approach
Avelar, M., Delgado-Acosta, P. F., Guzmán‐Ávila, R., & Flores‐Morales, V. (2025) · Results in Chemistry · doi:10.1016/j.rechem.2025.102481 · Cited by 4
Recent Advances and Future Directions in Alzheimer’s Disease Genetic Research
Stancheva, M., Toncheva, D. I., & Karachanak-Yankova, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167819 · Cited by 6
Identifying synergistic combinations of repurposed treatments for Alzheimer’s Disease
Ballard, C. G., Sultana, J., Doherty, P., Williams, G. H., & Corbett, A. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100329 · Cited by 7
“This complex interplay underscores the necessity of developing combination therapies that use a smart approach to targeting AD pathways to achieve the maximum synergistic benefit on disease progression [20].”
Biologics for the management of dementia
Chaurasiya, A., Katke, S., Panchal, K., & Nirmal, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824331-2.00001-7 · Cited by 6
Available Treatment Modules for Brain Disorders
Iman, T., Akram, R., Javed, M. S., Rasul, A., Sajid, F., Tehreem, A., Waris, S., & Hussain, G. (2023) · Food bioactive ingredients · doi:10.1007/978-3-031-41188-5_6 · Cited by 5
Nair, A. C., Benny, S., Aneesh, T. P., Sudheesh, M. S., & Lakshmi, P. K. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119024 · Cited by 5
Role of Computational Modeling in Drug Discovery for Alzheimer’s Disease
Yadav, M. R., Murumkar, P. R., Barot, R. R., Yadav, R., Joshi, K. D., & Chauhan, M. (2023) · Challenges and advances in computational chemistry and physics · doi:10.1007/978-3-031-33871-7_3 · Cited by 7
Nguyen, H. D. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2259482 · Cited by 5
“Furthermore, compound 18 can be combined with other drugs (non-P-glycoprotein substrates) to improve clinical efficacy (Kabir et al., 2020; Nguyen, 2022).”
Combinatorial therapy in Alzheimer's disease
Giri, M. A., Kendre, P. N., Bhalke, R. D., Pande, V. V., Autade, K. A., & Sumbe, R. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00026-1 · Cited by 7
Ahsan, R., Khan, S. A., Khan, M. M., Mishra, A., Ahmad, U., & Akhtar, W. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.106764 · Cited by 3
Fillit, H. M., Touchon, J., Vellas, B. J., Nisenbaum, L. K., & Burstein, A. H. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100327 · Cited by 4
“However, such combinations primarily address the symptoms of AD rather than addressing the underlying biology associated with the progression of the disease [27,28].”
Disparity of Prescribed Psychotropics in Alzheimer’s Disease with Neuropsychiatric Symptoms
Nathaniel, S. I., Oliver, M., Nathaniel, T. I., Roley, L. T., Goodwin, R. L., & Imeh‐Nathaniel, A. (2025) · Pharmacoepidemiology · doi:10.3390/pharma5010001 · Cited by 3
“Therefore, a common therapeutic target is acetylcholinesterase degradation [17,18].”
Kim, A.-L., Lee, W. K., Kwon, S., Han, I. B., & Choi, B. H. (2026) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-025-00782-1 · Cited by 6
Boeuf, W. L., Hefny, A. A., Karuturi, R. C., & Rao, P. P. N. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00760 · Cited by 5
Travers--Lesage, V., Since, M., Wang, A., Davis, A., Fayolle, D., Bernay, B., Modeste, F., Nachon, F., Brazzolotto, X., Crouzier, L., et al. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00170 · Cited by 3
Xiong, F., Li, C., Wang, Q., Geng, X., Yuan, Z., & Li, Z. (2023) · Journal of Molecular Neuroscience · doi:10.1007/s12031-023-02107-0 · Cited by 3
“The treatment of AD includes drug therapy (Kabir et al. 2020), including acetylcholinesterase inhibitors to improve cognitive function, N-methyl-D-aspartate receptor antagonists, Fig.”
MethodNguyen, H. D., & Kim, M. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2238068 · Cited by 3
“Additionally, it has been observed that the concomitant administration of these compounds with other drugs (non-P-glycoprotein substrates) can enhance their clinical efficacy (Kabir et al., 2020; Nguyen, 2022).”
Nair, A. C., Kuriakose, B. B., Biju, A., Surendran, S., Sudheesh, M. S., & Lakshmi, P. K. (2025) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2024.101041 · Cited by 3
“In this context, herbal drugs being multitargeted are gaining attention as a promising approach for the treatment and management of AD [7].”
Xie, Y., Hou, Y., Hu, M., Chen, H., Wang, H., Zhao, L., & Xu, J. (2025) · Biosensors · doi:10.3390/bios15020118 · Cited by 4
Wang, H., & Lv, P. (2025) · American Journal of Translational Research · doi:10.62347/yopp4162 · Cited by 4
“They pointed out that since AD pathogenesis is multifactorial, a multimodal therapeutic intervention targeting several molecular entities appears to be the most pragmatic approach to modify disease progression [25].”
Polypharmacology in Drug Design and Discovery—Basis for Rational Design of Multitarget Drugs
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_12 · Cited by 3
Novel therapeutic delivery for neurodegenerative diseases: Strategies to overcome CNS barriers
Doke, R. R., Naik, T., Lamkhade, D., Bhise, T. S., Khokrale, V. N., & Gosavi, Y. B. (2023) · Journal of Pharmaceutical and Biological Sciences · doi:10.18231/j.jpbs.2023.001 · Cited by 4
Alzheimer’s Disease: An Outline of Therapeutic Interventions by different Approaches
Dyuthi, H. Y., & Rajashekhar, U. (2024) · Research Journal of Pharmacology and Pharmacodynamics · doi:10.52711/2321-5836.2024.00038 · Cited by 3
Ohanube, G. A. K., Obeta, U. M., & Ikeagwulonu, R. C. (2022) · Biochemistry · doi:10.5772/intechopen.101051 · Cited by 3
Geerts, H., & van der Graaf, P. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210039 · Cited by 3
“A large number of combination therapies have been tested in clinical studies (for an excellent and comprehensive review, see [46]).”
BackgroundYong, A., Zhao, Y., Xu, H., Liu, Q., & Huang, C. (2023) · Acta Neurologica Belgica · doi:10.1007/s13760-023-02247-5 · Cited by 3
Bondt, E. D., Locquet, P., Lopez, M. F., Soysal, P., Welsh, T. J., Shenkin, S. D., Tournoy, J., & EuGMS Dementia Special Interest Group (2025) · European Geriatric Medicine · doi:10.1007/s41999-025-01165-4 · Cited by 4
“A review in 2020 confirmed that dual therapy exhibited better clinical efficacy than monotherapy with AChEIs in people with moderate-to-severe AD [51].”
γ-secretase targeting in Alzheimer's disease
Du, L., Li, G., Wei, Y., & Han, G. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251349529 · Cited by 4
“96,97 Alternatively, developing γ -secretase modulators with enhanced substrate speci fi city represents a promising approach to achieve targeted reduction of amyloid plaque deposition while preserving physiological Notch signaling.”
Combination Of Riluzole And Rivastigmine- A Potential Treatment Strategy For Alzheimer’s Disease
(2023) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.47750/jptcp.2023.30.04.031 · Cited by 2
Misiu̅naitė, I., Mikalauskaitė, K., Paulauskaitė, M., Sniečkutė, R., Smirnovas, V., Brukstus, A., Žiaunys, M., & Žutautė, I. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00451 · Cited by 2
Developing non-invasive molecular markers for early risk assessment of Alzheimer's disease
Sur, T. K., Mondal, T., Noreen, Z., Johnson, J., Nunlee‐Bland, G., Loffredo, C. A., Korba, B. E., Chandra, V., Jana, S. S., Kwabi‐Addo, B., et al. (2025) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2025.100120 · Cited by 4
“Common NMDA receptor antagonists include: Memantine (approved for moderate to severe AD), Namzaric (a combination of memantine and donepezil, approved for moderate to severe AD) (Kabir et al., 2020; Olivares et al., 2012).”
Khan, K. A., Esa, M., Kamal, Z., Ullah, B., Perry, G. L., Kamal, S., Ahmad, S., Hussain, H., Ullah, A., & Shafique, M. S. (2025) · Current Neuropharmacology · doi:10.2174/011570159x361867250313073624 · Cited by 2
“On the drug development front, significant progress has been made in identifying novel drug targets, including amyloid beta (Aβ) aggregation, tau phosphorylation, and inflammation.”
Primary Cilia and Cardiovascular Risk Factors in Alzheimer's Disease
Sunderman, C. L., Forero, K. V., Alorjani, Q., Buqaileh, R., Gallagher, G. M., Ventresca, S. M., Messer, W. S., & AbouAlaiwi, W. A. (2025) · Brain Sciences · doi:10.3390/brainsci15091004 · Cited by 1
“One of the most studied combination drug therapies is the use of memantine and cholinesterase inhibitors, which has proven clinical efficacy in the treatment of moderate to severe AD [140].”
Shawish, N. S., Kawafha, M., Kamel, A. M. A., Al-Maghaireh, D., & Hani, S. B. (2024) · Working with Older People · doi:10.1108/wwop-10-2023-0042 · Cited by 1
Ahmad, S. R., Zeyaullah, M., AlShahrani, A. M., Khan, M. S. A. A., Muzammil, K., Ahmed, F., Dawria, A., Mohieldin, A., Ali, H., & Altijani, A. A. G. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301179 · Cited by 3
Lin, L., Zhang, L., Li, C., Jin, L., Wang, R., Shu, Y., Chen, B., & Shen, Y. (2025) · Food Hydrocolloids for Health · doi:10.1016/j.fhfh.2025.100215 · Cited by 1
Pathophysiology of Alzheimer’s Disease: Herbal Neurogenesis and Synthetic Molecular Interventions
Kumar, A., Kumar, M., Verma, A., Joshi, R., Bidlan, M., & Singh, R. (2025) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-025-00304-2 · Cited by 2
“Until more rigorous studies are conducted, combining these approaches should be done cautiously and under medical supervision [76].”
Suryawanshi, V. S., Islam, M. S., Eldesoky, G. E., Patil, P. C., Bhowmick, S., & Islam, M. A. (2025) · ChemistrySelect · doi:10.1002/slct.202500492 · Cited by 1
Ella, F. A., Tchamgoue, J., Ambamba, B. D. A., Mountessou, B. Y. G., Mbappe, F. E., Essola, N. N., Wilhelm, A., Ngondi, J. L., Njayou, F. N., & Kouam, S. F. (2025) · Fitoterapia · doi:10.1016/j.fitote.2025.106967 · Cited by 1
Mechanisms to medicines: navigating drug repurposing strategies in Alzheimer’s disease
Khan, S. A., Raza, K., Tiwari, P., El‐Tanani, M., Rabbani, S. A., & Parvez, S. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1676065 · Cited by 4
Wang, B., Li, Y., Yao, T., Shen, X., Li, H., Jiang, W., Li, X., & Zhu, Z. (2026) · RSC Medicinal Chemistry · doi:10.1039/d5md00963d · Cited by 3
Extracellular matrix, amyloid fibrils and infections. Is there a new approach to combat amyloidosis?
Asti, A. L., Negri, E., Preda, S., Patel, L., & Colombani, C. (2026) · Journal of Medical Science · doi:10.20883/medical.e1392 · Cited by 1
Advances in the treatment of Alzheimer’s disease
Goceroglu, R. T., & Hacımüftüoğlu, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1819165 · Cited by 2
“Given the complexity of AD, the combination of therapeutic agents may be more effective than monotherapy (Deardorff and Grossberg, 2016; Agatonovic-Kustrin et al., 2018; Kabir et al., 2020).”
Pharmacological Approaches and Herbal Interventions for Alzheimer's Disease
Kumar, S., Singh, S., Rajput, D., Sharma, B., Chaturvedi, K., Singh, N., Saha, S., Singh, K., & Mukherjee, S. (2024) · The Natural Products Journal · doi:10.2174/0122103155275266231123090138 · Cited by 16
Potential Stem Cell Treatment for Alzheimer’s Disease with Possible Applications of Lithium Therapy
Caputo, T. J., Inayat, M. S., & Gallicchio, V. S. (2024) · Journal of Clinical and Laboratory Medicine · doi:10.16966/2572-9578.142 · Cited by 1
“The most common combinations include memantine and donepezil and memantine and galantamine which can act together to deliver synergistic neuroprotection for individuals with moderate to severe Alzheimer’s disease [24].”
BackgroundStem cell-based therapy for Alzheimer’s disease
Belousova, E. V., Salikhova, D. I., Nebogatikov, V. O., Ustyugov, A. A., & Goldshtein, D. V. (2024) · Laboratornye Zhivotnye dlya nauchnych issledovanii (Laboratory Animals for Science) · doi:10.57034/2618723x-2024-01-06 · Cited by 1
Putilina, M. V. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-278 · Cited by 1
Safety and effectiveness of Donepezil and Memantine in Alzheimer's Disease
Ghosh, A. (2025) · International Journal of Pharmaceutical Sciences and Drug Research · doi:10.25004/ijpsdr.2025.170310
Ahmad, S. R., Zeyaullah, M., Zahrani, Y. I., Khan, M. S., Muzammil, K., & Dawria, A. (2025) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2025.109135 · Cited by 1
Emelin, А. Y., & Lobzin, V. Y. (2020) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2020-4-131-136 · Cited by 2
Camarillo-López, R. H., Rodríguez, M. H., Torres-Ramos, M., Arciniega-Martínez, I. M., García-Marín, I. D., Correa‐Basurto, J., Méndez‐Méndez, J. V., & Rosales‐Hernández, M. C. (2020) · Molecules · doi:10.3390/molecules25215009 · Cited by 1
“Due to the multifactorial pathogenesis of AD, the use of a multimodal therapeutic intervention addressing several molecular targets of AD-related pathological processes seems to be the most practical approach to modify the course of AD progression [19].”
BackgroundHaratake, Y., Sano, K., Tsuchiya, M., Minaki, K., Munekane, M., Yamasaki, T., Hagimori, M., & Mukai, T. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116591 · Cited by 1
Copolymer-1 as a potential therapy for mild cognitive impairment
Abraham, D. I., Salazar, F. E., & Ibarra, A. (2022) · Brain and Cognition · doi:10.1016/j.bandc.2022.105892 · Cited by 1
Ahmad, F., Abiha, U., Ahmad, S., & Patel, N. (2023) · Research Square · doi:10.21203/rs.3.rs-2879310/v1 · Cited by 1
Bartholomew, S. K., Turk, J., Winslow, W., Foley, C., Shaw, A. Y., Rokey, S., Tallino, S., Judd, J. M., Beach, T. G., Serrano, G. E., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.20.700091 · Cited by 2
Mechanism, Diagnosis, Medication, Care Guidance, and Health Promotion in Alzheimer’s Disease
Dong, Y. (2020) · E3S Web of Conferences · doi:10.1051/e3sconf/202021803047
“According to the detailed review from [34], Table 6 for currently researched CTs with its effect and progress is concluded.”
BackgroundMethodInfluentialPhotogenerated Iodine for Determination of Active Pharmaceutical Ingredients in Tetralgin Drug
Турусова, Е. В., & Насакин, О. Е. (2021) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-021-02486-x
Drug information of Aducanumab and its effectiveness for Alzheimer’s disease: A clinical review
Raval, N. S., Chavda, S. A., Mithaiwala, D. N., Nayak, S. P. S., Buddhdev, M., & Chakraborthy, G. S. (2021) · International Journal of Biological and Pharmaceutical Sciences Archive · doi:10.53771/ijbpsa.2021.2.2.0094
Hsieh, K., Plascencia‐Villa, G., Lin, K., Perry, G. L., Jiang, X., & Kim, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1261984/v1
Oluwadahunsi, G., Akinwotu, S., Fadipe, T. M., Akintoye, O. P., Omoyajowo, T. J., Ologuntere, E. T., & Abdullah, Z. (2022) · International Journal of Biochemistry Research & Review · doi:10.9734/ijbcrr/2022/v31i130299
Emerging Roles of TREM2 in Neurodegenerative Diseases
Kabir, M. T. (2022) · Springer eBooks · doi:10.1007/978-981-16-7606-2_7
Self-citationMolecular Insights into the Role of ER Stress in Neurodegenerative Diseases
Kabir, M. T. (2022) · Springer eBooks · doi:10.1007/978-981-16-7606-2_9
Self-citationPolypharmacology in Clinical Applications: Neurological Polypharmacology
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_6
da Silva, J. R. M. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.87.2021.tde-08122022-121034
Hou, X., Jiang, H., Liu, T., Yan, J., Zhang, F., Zhang, X., Zhao, J., Mu, X., & Jiang, J. (2022) · Research Square · doi:10.21203/rs.3.rs-2351885/v1
Nameni, F., & Firoozmand, F. (2022) · Jorjani Biomedicine Journal · doi:10.52547/jorjanibiomedj.10.2.36
Edible Bird’s Nest: Seeing the Unseen
Mohamed, W. M. Y. (2023) · Nutritional neurosciences · doi:10.1007/978-981-99-1513-2_6
Blood brain barrier and its significance in drug delivery to brain in Alzheimer disease
Rana, D., Salave, S., Khunt, D., & Benival, D. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00018-2 · Cited by 2
O-demethyl Galantamine Alters Protein Expression in Cerebellum of 5xFAD Mice
Kiris, İ., Karayel‐Basar, M., Gürel, B., Mroczek, T., & Baykal, A. T. (2024) · TURKISH JOURNAL OF BIOLOGY · doi:10.55730/1300-0152.2692 · Cited by 1
“Studies have shown that combination therapies are much more successful in AD than single-target therapies due to the complex nature of the disease (Tanvir Kabir et al., 2020; Uddin et al., 2021).”
BackgroundDifferent drugs used as therapeutic targets against AD till date
Nahar, M., Khan, A. G., Rai, R., & Jat, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15540-6.00009-4
Tandon, S., & Sarkar, S. (2024) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2024.106690
Research Progress and Future Development Directions of Alzheimer’s Disease
Jin, J. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2024.la19856
Upcoming Nano and Conventional Drug Delivery Strategies for Alzheimer’s Disease
Varghese, N. M., Sathyamoorthy, N., Krishnamurthy, P. T., Varshini, M. S., & Chintamaneni, P. K. (2024) · Springer eBooks · doi:10.1007/978-981-96-0259-9_16 · Cited by 1
Thawkar, B. S., & Kaur, G. (2025) · Minerva Biotechnology and Biomolecular Research · doi:10.23736/s2724-542x.24.03153-5 · Cited by 1
Acetylcholinesterase Inhibition and Antioxidant Activity of DHA‐Disubstituted Phospholipids
García-Quinto, E., Sollecito‐Rovella, S., Luna, V. M. A., Montero, L., & Fernández‐Lorente, G. (2025) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70095 · Cited by 1
“Moreover, galantamine is contraindicated in patients with significant renal or hepatic impairment, highlighting the need for alternative or complementary therapeutic approaches [29].”
Selvaa Kumar, C., Yegnaswamy, S., Dasgupta, D., Johari, P., & Harish, M. (2025) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2025.2543373
“The current treatment strategies predominantly provide symptomatic relief, primarily through the use of cholinesterase inhibitors (Kabir et al., 2019; 2020).”
Curing Alzheimer’s disease: Magic bullet or magic shotgun blast?
Weaver, D. F. (2025) · The Conversation · doi:10.64628/aam.d7cgqw5un
Donepezil: cholinesterase inhibitor for the treatment of Alzheimer's disease
Singh, V. K., Rai, S., & Singh, R. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33885-4.00040-8
Yuan, C., Lv, S., Han, Y., Li, Y., Xian, Z., Liu, G., & Xiao, S. (2025) · ACS Omega · doi:10.1021/acsomega.5c05682
“38 Considering the various bioactive functions summarized above, quercetagitrin might be a potential leading compound for the treatment of AD.”
Nutraceuticals intervention in Alzheimer's disease: From farm to pharma
Chaithra, P. M., Rakshith, B. S., Logesh, S., Basalingappa, K. M., Gopenath, T. S., Chang, H., Perry, G. L., & Singh, S. K. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251385216 · Cited by 1
Exploring boswellic acids as a multitarget therapeutic treatment for Alzheimer’s disease
Patil, D. N., & Barvkar, V. T. (2026) · Journal of Biologically Active Products from Nature · doi:10.1080/22311866.2025.2610615 · Cited by 1
Suo, W. Z. (2026) · Neuropharmacology and Therapy · doi:10.15212/npt-2025-0012
Metadata
- Authors
- Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M.
- Affiliations
- BRAC University (BD)
- Southeast University (BD)
- Centre National de la Recherche Scientifique (FR)
- King Abdulaziz University (SA)
- Division of Drug Design and Medicinal Chemistry Research Lab, Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy, Palakkad 678557, India
- Princess Nourah bint Abdulrahman University (SA)
- Department of Zoology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia
- Corresponding author
- Uddin, Md. Sahab
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-05-05
- Volume
- 21
- Issue
- 9
- Pages
- 3272
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7246721
- OpenAlex
- W3022707404
- Cited by
- 217
- References
- 135
- Citations by year
- 2026: 26 · 2025: 43 · 2024: 34 · 2023: 30 · 2022: 40 · 2021: 27 · 2020: 17
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- HAL (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Griffith Research Online (submittedVersion, cc-by)
- Funders
- Princess Nourah Bint Abdulrahman University
- Deanship of Scientific Research, Princess Nourah Bint Abdulrahman University
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, combination therapy, multimodal therapy, disease-modifying therapy, symptomatic treatment, early intervention, cognitive impairment, drug safety and tolerability, drug efficacy
- MeSH terms
- Alzheimer Disease, Animals, Cholinesterase Inhibitors, Clinical Trials as Topic, Disease Susceptibility, Drug Therapy, Combination, Galantamine, Humans, Memantine, Dopamine Agents, Biomarkers, Disease Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.